Microbix announces new product development program to help combat Zika virus
Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus.
Microbix Biosystems has announced plans to develop and introduce new products for use in diagnostic tests and vaccine research in response to the emergent Zika virus, which is spreading throughout the Americas and is being characterized as a crisis by health authorities.
Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus, including native molecular controls, live and inactivated forms of the antigen, and related biological materials. These products will aid in the development of assays with high specificity and low cross-reactivity to related tropical diseases, including Dengue, that are spreading into formerly temperate climates as the geographic range of host mosquitos expands.
The World Health Organization (WHO) reports the Zika virus is spreading rapidly in the Americas, and it is being linked to babies born with abnormally small heads and other possible birth defects. Approximately one in 200 babies born in Brazil have been affected since the onset of the crisis in late 2015. The Director General of the WHO has declared an international public health emergency as the mosquito-borne Zika virus has gone from being "a mild threat to one of alarming proportions."
Vaughn Embro-Pantalony, Microbix' CEO and President commented: "The close relationship between Zika and Dengue viruses places Microbix in a unique position to help meet the challenges of this emerging health threat. Our expertise in growing Dengue virus at large scale, together with our processes for delivering diagnostic products for Dengue, will allow us to efficiently produce these new Zika virus products once their development is complete. We believe our products will be pivotal for the accurate diagnosis of this infection, which will help health authorities more effectively respond to this crisis, and will benefit patients as well as those at risk."
Dr Mark Luscher, Microbix' Senior Vice-President and Chief Scientific Officer explained: "Zika virus infection may progress without symptoms or it may be associated with a mild fever or rash, making it very difficult to detect the presence of the virus early in the infectious phase. Microbix' virus products are often used to detect antibodies produced by the body during infection. Such antibodies last long after the infection is gone, and thus are a vital indicator to health care professionals that a person has been infected with the virus. In the case of Zika, this information may be critical to the health of the individual and an unborn child. The need for this type of health information has already led to Microbix' Rubella, Toxoplasmosis and CMV products being used to test women of childbearing age throughout the world."
"The Zika virus will be cultured and purified as a basis for immune testing for current or past infection," continued Dr Luscher. "Microbix is also producing a Red Controls Zika preparation to help reference laboratories in Zika-affected countries. We intend to complete development of these Zika-related products as soon as possible."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance